Agilent CDx News & Events

Explore Agilent CDx's latest news and events

Agilent has been leading companion diagnostics (CDx) for over 25 years. Having co-developed the first CDx on market, Herceptest for Herceptin in 1998, Agilent continues to make a mark on the CDx industry with innovative approaches to assay development. We collaborate closely with pharmaceutical companies to develop targeted therapies on a global scale.

Browse our latest innovations, speaking events and the partnerships we are creating to make precision medicine a reality for patients around the world.

CDx in the News

Agilent Companion Diagnostic Assay PD-L1 IHC 28-8 pharmDx Receives European IVDR Certification

Announcing the issuing of a Class C companion diagnostic In Vitro Diagnostic Regulation (IVDR) certification for PD-L1 IHC 28-8 pharmDx (Code SK005)

Agilent Unveils Biopharma CDx Services Lab to Accelerate Precision Medicine

New CLIA-certified lab ensures seamless transition from early assay development and testing to full companion diagnostics commercialization

Agilent Nabs FDA Approval for Soft Tissue Cancer CDx

The MAGE-A4 IHC 1F9 PharmDx assay is used to guide the treatment of synovial sarcoma patients with Adaptimmune Therapeutics' newly approved treatment Tecelra.

New

Agilent Receives FDA Approval for MAGE-A4 IHC 1F9 pharmDx as a Diagnostic Tool for Use with Newly Approved TCR T-Cell Therapy

MAGE-A4 IHC 1F9 pharmDx is indicated as an aid in identifying patients with synovial sarcoma for whom TECELRA®, a MAGE-A4-directed engineered T-Cell Receptor (TCR) therapy is being considered

New

Complex Therapies, Complex Diagnostics

Learn about Agilent's efforts in creating companion diagnostics for innovative drug classes such as Antibody-Drug Conjugates (ADCs), bi- and tri-specific antibody therapies and immuno-oncology combination therapies.

New

Inside Precision Medicine: New Frontiers in CDx Development

In the latest Inside Precision Medicine, CDx VP/GM Paul Beresford discusses industry-leading innovations in early-stage diagnostics, digitalization and machine learning.

New

Opportunities & Challenges of Digital Pathology Adoption in CDx Development

In this new podcast by Fierce Pharma, two of our industry experts, Grace Lee, AVP of CDx Global Regulatory Affairs and Douglas P. Clark, MD, Chief Pathologist of CDx explore the vast opportunities and challenges associated with implementing AI and digitalpathology into CDx development.

Transcenta Announces Collaboration with Agilent to Develop a Claudin 18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial

Agilent and Transcenta presented the early results of the Claudin 18.2 IHC 14G11 pharmDx assay at AACR Annual Meeting.

Agilent Announces Collaboration with Incyte to Develop Advanced Companion Diagnostics in Hematology and Oncology

The partnership will leverage Agilent's expertise in assay development with Incyte's innovation in drug discovery.

Addressing pharma's evolving needs for CDx development

In this podcast by Fierce Pharma, CDx VP/GM Paul Beresford and Pathology VP/GM Lou Welebob discuss the advantages of pharma partnerships and look ahead to the future of CDx.

Tissue-Based Multiplex Biomarker Assays and Companion Diagnostics

From the Journal of Precision Medicine, Agilent CDx gives an overview of multi-plexing, a technology Agilent uses to develop complex companion diagnostics.

Editorial Article: Tools to advance precision oncology

Dr. John Palma, Global Head of Medical Affairs at Agilent, offers insights into the technologies driving the field of precision oncology

Agilent Aims to Ramp up Early-Stage CDx Development Deals

CDx VP/GM Paul Beresford on Agilent's steps toward becoming a one-stop shop for early-stage precision oncology research, including AI partnerships and Agilent's upcoming Biopharma CDx Services Lab.

Visit the Agilent Newsroom for all press releases and media coverage.

Agilent CDx 2024 Events

Jan 8-11

JP Morgan Healthcare Conference, San Francisco

March 23-28

USCAP, Baltimore

March 26-28

Precision Med Tri-con, San Diego

April 4

Agilent CDx Symposium, Santa Barbara

April 5-10

AACR, San Diego

April 23-25

World CB & CDx Europe, London

June 1-5

ASCO, Chicago

Aug 19-21

Next-Gen Dx Summit, Washington D.C.

Sept 3-6

World CB & CDx, Boston

Sept 13-17

ESMO, Barcelona, Spain

Nov 6-10

SITC, Houston

Nov 12-13

Personalized Medicine Conference, Boston

Agilent CDx Symposium

Emerging trends in drug development and CDx

Pioneering CDx and precision medicine

Precision medicine is revolutionizing therapy selection

Accelerate your CDx development program by leveraging our broad technical and regulatory expertise, global infrastructure and decades of proven experience. Our portfolio of cutting-edge technologies and biomarkers allows for diverse and comprehensive solutions for your precision drug development programs.

Watch video

For more information about Companion Diagnostics at Agilent, visit our CDx home

Visit CDx home

D0117897_1.00